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Granulomatosis with polyangiitis 
Granulomatosis with polyangiitis (GPA) is a rare systemic autoimmune disease characterized by 
inﬂammation of the small- and medium-sized blood vessels and is strongly associated with the 
presence of anti-neutrophil cytoplasmic autoantibodies (ANCA) directed against proteinase 3 
(PR3)1. The clinical spectrum of GPA is broad comprising localized, early systemic, generalized 
and severe forms of the disease2, 3. In localized GPA, disease manifestations are restricted to the 
upper and/or lower respiratory tract whereas in the generalized form of the disease the systemic 
vasculitis aﬀects more organs often including the kidneys. In many cases the disease starts 
locally and gradually progresses to a more generalized form, whereas only few patients remain 
in the localized disease stage. Histopathologically, GPA is characterized by necrotizing vasculitis, 
necrotizing glomerulonephritis and granulomatous inﬂammation.
To date the etiology of GPA remains unclear but is clearly multifactorial in which environmental 
factors, genetic predisposition and disturbances in cellular immune responses contribute to 
disease development and progression4-7.
Current treatment of GPA consists of two phases of immunosuppressive therapy8. The ﬁrst 
phase aims at induction of remission and a rapid control of disease activity to prevent irreversible 
tissue damage. The second phase is directed at preventing disease ﬂares. This treatment strategy 
exposes patients to long-term broad acting immunosuppressive drugs (e.g. cyclophosphamide 
and glucocorticoid steroids) which has considerably improved patients’ survival but comes at 
the cost of substantial adverse side eﬀects such as a high rate of infection and drug toxicity9. 
Furthermore, many GPA patients suﬀer from frequent disease relapses during drug tapering or 
discontinuation of treatment10. Consequently, each relapse is associated with an increased risk of 
cumulative tissue damage9 requiring reinitiation of immunosuppressive treatment emphasizing 
the need for less toxic and more selective treatment approaches in GPA. 
To develop a speciﬁc and selective therapy that targets eﬀector immune pathways, a better 
understanding of the immune pathophysiology of GPA is required. Over the past two decades 
it has become clear that dysregulation in cellular immunity is a critical component of the 
pathogenesis of GPA. Hence, the role of T and B cells in GPA pathogenesis has received increasing 
interest. Observational studies on peripheral and lesional T cells in GPA suggest that various T cell 
subsets may contribute to the pathogenesis of GPA although the underlying eﬀector pathways 
are only partially understood7. Also, more recent studies in GPA patients have demonstrated 
alterations in peripheral B cell subset distribution which may aﬀect both antibody-independent 
regulatory and eﬀector B cell functions11. Thus, disturbances in both the T and B cell compartment 
in GPA patients are likely to be involved in GPA pathogenesis. 
In this thesis we investigated a potential novel therapeutic strategy in GPA, speciﬁcally 
directed against eﬀector subsets of CD4+ T helper (T
H
) cells and B cells while keeping other, 
beneﬁcial, immune cells unaﬀected. Since both T
H
 eﬀector cells and B eﬀector cells are uniquely 
dependent on Kv1.3 potassium channels for cellular activation, we hypothesized that blocking 
these channels with the highly potent Kv1.3 channel inhibitor ShK-186 would eﬀectively suppress 
the pro-inﬂammatory eﬀector responses of these cells. To further our insights in immune 
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mechanisms involved in GPA pathogenesis, we also studied the phenotype of circulating CD4+ 
T
H
 subsets in GPA patients in more detail and investigated the potential interplay between 
regulatory B cells and the expanded T
H
17 population in GPA patients. 
T cell phenotypes in GPA
T cells are critical players in regulating immune responses. Failure of an adequate control of T cell 
activity may result in unwanted eﬀects such as chronic inﬂammation and autoimmune disease, 
both hallmarks of the pathogenesis of GPA. An overview of the T cell mediated immune responses 
that contribute to chronic vascular inﬂammation – a manifestation of GPA as well as atherosclerosis 
– is described in chapter 27. In particular, we have discussed the key contribution of distinct CD4+ T
H
 
cell subsets in GPA pathogenesis. The ﬁrst studies on T
H





2 responses in relation to the stage of the disease since it was hypothesized that a 
shift in T cell response could be of pathogenic importance in the transformation from localized 
to generalized GPA. These studies suggested a dominance of T
H
1 responses in GPA patients with 
localized disease whereas in patients with active generalized disease T
H
2 responses appeared 
more prevalent12-16. However, later studies indicated that the distinction between localized and 
generalized GPA based on the type of T
H
 cell response was less clear than previously thought since 
IFN-γ producing T
H
1 cells could readily be detected in the circulation and lesional airway tissues of 
GPA patients with active generalized disease as well17, 18. 
In the early 2000’s, a distinct novel subset of CD4+ T eﬀector cells was described that was 
named T
H
17 cells due to their characteristic production of pro-inﬂammatory molecules of the 
IL-17 family19. Subsequent studies revealed a prominent role of T
H
17 cells in inﬂammation and 
autoimmunity leading to a wealth of studies in various autoimmune diseases including GPA20. 
It has been reported that GPA patients, both during active disease and remission, display an 
expanded pool of circulating T
H
17 cells, elevated levels of serum IL-17 and increased numbers 
of auto-antigen speciﬁc T
H
17 cells21, 22, 23, 24. The major physiological role of T
H
17 cells lies within 
the defense against bacterial infections, for example Staphylococcus aureus (S. aureus) infections. 
Intriguingly, chronic nasal carriage of S. aureus has been reported to be a risk factor for disease 
relapse in GPA patients25. Therefore, it has been postulated that chronic carriage of S. aureus 
might drive a T
H
17 response in GPA. Moreover, IL-17 facilitates the migration and activation 
of neutrophils by promoting the secretion of TNF-α and IL-1β26. Since the accumulation of 
neutrophils is a hallmark of the early eﬀector phase of GPA, T
H
17 cells might be important drivers 
of the recruitment and activation of neutrophils during active vasculitis. Together, these data 
provide important evidence for the involvement of T
H




 eﬀector functions, including those of T
H





 cells are a distinct CD4+ T cell subset characterized by their potent immunosuppressive 





are characterized by considerable phenotypic and functional plasticity28 determined by the 
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the transcription factor RORγt, which is characteristic for T
H
17 cells and necessary for IL-17 
production28. On the other hand, FoxP3, the signature transcription factor of Tregs, negatively 
regulates IL-17 production via direct physical interaction with RORγt29. Interestingly, the pro-
inﬂammatory cytokine, IL-6 suppresses FoxP3 expression. Consequently, no inhibition of RORγt 
occurs allowing T cells to diﬀerentiate towards T
H
17 cells29, 30. Therefore, it might be possible that 
the expanded T
H
17 population in GPA is due to a decline in the number of T
REG
 cells or their 
impaired functionality caused by malfunctioning of FoxP3, both of which have been implicated 
to contribute to the pathogenesis of GPA31-33. 
The lineage committed eﬀector T
H






17 cells can be classiﬁed 
within the antigen-experienced CD4+ eﬀector memory T (T
EM
) cells. In GPA, studies reported 
that T cells with a memory phenotype are a major source of IFN-γ and IL-1718, 34. Our group 
previously studied the frequency of CD4+ T
EM
 cells in GPA and found that the circulating CD4+ 
T
EM
 cells are proportionally increased in GPA patients during remission but are decreased during 
active disease35. Interestingly, the CD4+ T
EM
 cells appear in the urinary sediment of active GPA 
patients with renal involvement36. This observation suggested that CD4+ T
EM
 upon active disease 
migrate from the circulation to the inﬂammatory sites in the kidneys. Moreover, T cells with 
a memory phenotype were also observed in the nasal cavity of GPA patients with localized 
disease15. However, not all CD4+ T
EM
 cells tend to migrate to  target tissues. It is possible that the 
diﬀerent phenotypes among the circulating CD4+ T
EM
 cells reﬂect distinct migratory capacities 
and pathogenic functions in GPA patients related to the various clinical manifestations. 
In chapter 3 we determined the distribution of circulating CD4+ T
EM
 cell subsets in GPA 
patients based on the co-expression of surface chemokine receptors37. Chemokine receptors 
have been particularly useful for distinguishing CD4+ T
EM
 cell subsets with distinct migratory 
capacities and eﬀector functions38. For instance, CXCR3 is expressed on IFN-γ producing T
H
1 cells; 
CCR6 is expressed on IL-17 producing T
H
17 cells; and CRTh2 is expressed on lineage-committed 
T
H
2 cells. Analyzing the expression of these chemokine receptors allowed us to identify distinct 
CD4+ T
EM








17.1) in the circulation of GPA and healthy 
individuals. Moreover, T cell phenotype analysis based on chemokine receptor expression 
allowed us to investigate diﬀerent CD4+ T
EM
 cell phenotypes without any in vitro stimulation 
or manipulation. This is in contrast to most previous studies in GPA analyzing T cell phenotype 
distribution of GPA patients using in vitro stimulation assays which may have inﬂuenced the T cell 
phenotypes. Therefore, by analyzing the chemokine receptors on the surface of T cells directly 
after blood withdrawal we expected to obtain a T cell phenotype distribution proﬁle resembling 
most closely the physiological distribution of circulating T cells in GPA patients. The results 
presented in chapter 3 demonstrate a signiﬁcant increase in the proportion of T
EM
17 cells with 
a concomitant decrease in the proportion of T
EM
1 cells in the peripheral blood of GPA patients in 
remission37. Furthermore, the increased proportion of T
EM
17 cells was more pronounced in GPA 
patients with systemic manifestations, whereas GPA patients with local manifestations showed 
a remarkable increase in T
EM





cells appeared to be associated with CMV seropositivity. 
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17 cells produce IL-17A and IL-17F, both signature cytokines that deﬁne this subset39. 
IL-17A and IL-17F are similar in their biological activity, targeting both immune and non-immune 
cells, and play an important role in inﬂammatory responses. IL-17 induces chemokine CXC ligand 
(CXCL)8 production from epithelial cells, endothelial cells, ﬁbroblast and macrophages leading 
to the recruitment of neutrophils. In addition, several cell types in chronically inﬂamed tissues 
produce chemokine CC ligand (CCL)20 in response to IL-1740, 41. CCL20 binds to the chemokine 
receptor CCR6, which is expressed on T
H
17 cells42. In GPA patients, Fagin et al found increased 
frequencies of circulating CCR6+ CD4+ T cells and showed that the expression of CCR6 was largely 
conﬁned to the memory T cell compartment43. Furthermore, they found that the CD4+CCR6+ 
T cell population contained distinct cytokine-producing cells that mainly produced IL-17. In 
addition, serum CCL20 has been found up-regulated in GPA patients24. Our present ﬁndings 
regarding the increase in the frequency of circulating T
EM
17 cells in GPA patients are in line with 
previous reports21-24. Collectively, these results underscore the critical involvement of T
H
17 cells 
in the pathogenesis of GPA, although it remains unclear which mechanisms initiate the T
H
17 
response in GPA. As described in chapter 2, a possible explanation for the expanded T
EM
17 
population might be the presence of chronic nasal carriage of S. aureus and the aberrant function 
of T
REG
 cells in GPA patients7. Since T
H
17 cells participate in the host defense against fungi and 
extracellular bacteria such an association might be possible. Indeed, it has been demonstrated 
that S. aureus-speciﬁc T
H
17 cells produce IL-17, and express RORγt and CCR644. Interestingly, it 
has also been reported that in vivo primed S. aureus-speciﬁc memory T
H
17 cells isolated from 
healthy donors produce IL-17 and IL-10. The production of IL-10 by T
H
17 cells was shown to be 
regulated by the polarizing cytokines produced by monocytes (i.e. IL-6, IL-23 and IL-1β) exposed 
to S. aureus and appeared to be present only in a narrow time window by strongly activated 
proliferating T
H
17 cells44. However, our analysis of T
EM
17 associated chemokine receptors did not 
show a correlation with S. aureus carriage in GPA patients37. This lack of association may be due 
to the fact that the selection of GPA patients in this study was not based on a recurrent activity 
of S. aureus. Therefore, the microenvironment needed to initiate skewing towards T
EM
17 cells was, 
at the time of sampling, not present. 
An additional contribution to T
H





 are characterized by the secretion of IL-21. Initially, it was described that these cells 
provide help to B cells and  stimulate humoral responses. However, in addition to the eﬀects 
on B cells, IL-21 is now known to promote the generation of T
H
17 cells as well45. Previously, our 
group demonstrated increased frequencies of IL-21 producing T cells in GPA patients and found 
a positive correlation between the frequencies of IL-21 producing T cells and IL-17 producing T 
cells46. 
The observed expansion of the T
EM
17 population may also be inﬂuenced by disturbances in 
the B cell compartment. In particular regulatory B (B
REG
) cells have been described to modulate 




17 cells and support the diﬀerentiation towards T
REG
 cells47. 
The possible interplay between B
REG
 and the T
EM
17 expansion is described in chapter 6 and 
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In addition, it has been reported that a persistent (latent) cytomegalovirus (CMV)-infection is 
associated with changes in the immune phenotype of lymphocytes. CMV infection primarily 
results in an altered distribution in the memory T cell compartment48. In GPA patients, expansion 
of CD4+CD28- T cells is associated with increased risk of infection and mortality and it has been 
suggested that this expansion is driven by CMV infection49. In line with these observations, 
we observed that CMV seropositive patients had an altered distribution of the CD4+ T
EM
 cell 









17 proportions present in CMV 
seronegative and seropositive healthy controls (chapter 3) 37. In contrast, in CMV seronegative 




17 showed a strong disease related phenotype pattern with 
decreased levels of T
EM
1 cells and increased levels of T
EM
17 cells. Therefore, it seems that persistent 




17 cells towards 
levels present in healthy controls. 
The identiﬁcation of CD4+ T
EM
 subsets based on chemokine receptor expression revealed 




17 cells of GPA patients in remission. The disturbed 
balance was shown to be associated with severity of the disease in terms of organ involvement 




17 cells is modulated 
in CMV seropositive GPA patients in remission. Accordingly, it is of great importance for future 
studies in GPA to carefully stratify and compare patient groups based on the disease activity, 
disease category (i.e. localized, early systemic, generalized or severe), duration of remission and 
persistent presence of (latent) infections such as CMV, as these factors may inﬂuence the T
H
 cell 
repertoire. Eventually, longitudinal studies in properly stratiﬁed patients groups that monitor 
changes in the CD4+ T
H







 balances when GPA disease progresses. 
Selective targeting of effector memory T cells in GPA by a Kv1.3 blocker
Increased CD4+ T
EM
 cells in the urine of GPA patients with active renal involvement and the 
aberrant distribution of CD4+ T
EM
 cell subsets in the circulation indicates their contribution to 
disease pathogenesis and their involvement in tissue damage. Therefore, selective targeting 
of these CD4+ T
EM
 cells may have great added value in the treatment of GPA. Interestingly the 
activation of the CD4+ T
EM
 cells is uniquely dependent on the voltage-gate Kv1.3 potassium 
channels50. In chapter 4 we investigated whether inhibiting the activation of CD4+ T
EM
 cells via 
speciﬁc blockade of the Kv1.3 channel using ShK-186 protects against pro-inﬂammatory eﬀector 
functions of CD4+ T
EM
 cells in GPA patients. 
The voltage-gated Kv1.3 potassium channels are the most prevalent potassium channels 
expressed by human T lymphocytes50. The Kv1.3 channels are important for the biological activity 
of T
EM
 cells, which are considered major mediators in autoimmune diseases51, 52. The engagement 
of the T cell receptor (TCR) by antigen presenting cells (APC) results in an inﬂux of calcium 
into the cytoplasm, initially from the endoplasmic reticulum (ER) and subsequently from the 
extracellular space via the Ca2+ release–activated Ca2+ channels50. Opening of the Kv1.3 channel 
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in the T cell membrane and the resulting eﬄux of potassium promotes the entry of calcium to 
sustain the intracellular calcium levels at concentrations necessary for T cell activation50. Resting 
T cells express low levels of Kv1.3 channels. However, upon activation T
EM
 cells uniquely up-
regulate Kv1.3 channel expression whereas the expression level of Kv1.3 on activated naïve T cells 
and central memory T cells (T
CM
) equals that of their resting state51. 
Previously, it has been shown that in autoimmune diseases T
EM
 cells expressing high levels 
of surface Kv1.3 channels are present at sites of inﬂammation, such as in the synovial ﬂuid of 
rheumatoid arthritis (RA) patients, and in the circulation as demonstrated in patients with multiple 
sclerosis (MS) and type 1 diabetes (T1D)51, 52. In addition, speciﬁc Kv1.3 channel inhibitors have been 
found to be eﬀective in ameliorating inﬂammation in numerous animal models of autoimmune 
diseases including chronic relapse-remitting experimental autoimmune encephalomyelitis (CR-
EAE), adoptive EAE, pristane-induced arthritis (PIA), delayed type hypersensitivity (DTH), and 
anti-glomerular basement membrane (anti-GBM) glomerulonephritis52-56. This motivated several 
research groups to focus on the development of speciﬁc and potent Kv1.3 channel inhibitors for 
the treatment of inﬂammation and autoimmune diseases. In particular, the identiﬁcation of the 
Kv1.3 channel blocker extracted from the Caribbean Sea anemone Stichodactyla helianthus toxin 
termed ShK57 has led to extensive studies regarding its therapeutic applicability. One striking 
aspect of ShK is its extreme potency to block voltage-gated potassium channels. In fact, it is the 
most potent Kv1.3 blocker described thus far58, but it also potently blocks other channel isotypes 
expressed in various tissues like the Kv1.1 (cardiac tissue) and Kv1.6 (brain tissue) channels59-61, 
raising concerns about potential cardiac and neuronal toxic side eﬀects. However, development 
of chemically synthesized analogs of ShK has improved the selectivity and stability of the 
peptide tremendously. The main lead peptide ShK-186 has a > 100-fold increased selectivity for 
Kv1.3 over Kv1.1 and >1000-fold over Kv1.660. The relative safety of ShK-186 may also be due to 
the structural composition of Kv1.3 channels on T cells. The Kv1.3 channels expressed on T cells 
are present as homotetramers whereas Kv1.3 channels expressed on other cell types are present 
as heteromultimers in which Kv1.3 forms heteromeric channels with other Kv1 subfamilies such 
as the Kv1.1, Kv1.2, Kv1.4 and Kv1.6 channels as it does for instance in neurons62, 63. Furthermore, 
toxicity and safety studies of ShK-186 showed it to have an excellent safety prolife in animal 
models52, 53, 64. In additon, ShK-186 was reported to exhibit no perceptible in vitro toxicity, was 
negative in the ames test, and had no eﬀect on cardiac parameters53. Furthermore, repeated 
subcutaneous administration of ShK-186 in rats did not cause clinical toxicity as indicated 
by normal blood cell counts and serum chemistry parameters, and it did not cause any 
histopathological changes in various tissues examined (brain, heart, lung, kidney) 52, 53. Moreover, 
in vivo studies have demonstrated that the eﬃcacy of ShK-186 can be achieved without causing 
general immunosuppression64. In rats, administration of ShK-186 did not compromise the 
protective immune response to acute viral (Inﬂuenza) or bacterial (Chlamydia) infections at 
pharmacological doses that did ameliorate autoimmune disease manifestations64.
In chapter 4 we demonstrated that the increased pro-inﬂammatory cytokine production 
in CD4+ T
H
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in line with previous in vitro studies showing that ShK-186 preferentially inhibited IL-2, IFN-γ, and 
TNF-α production by T
EM
 cells derived from the synovial ﬂuid from RA patients, blood derived 
myelin antigen–speciﬁc T cells from MS patients or islet antigen–speciﬁc T cells from type 1 
diabetes mellitus patients52. Additionally, ex vivo stimulation of whole blood from cynomolgus 
monkeys treated with ShK-186 resulted in reduced expression of IL-2, IFN-γ and IL-1765. Next, Chi 
et al showed similar ex vivo results using human whole blood treated with ShK-18660. Remarkably, 
they observed that ShK-186 was most eﬀective in suppressing the production of IL-2 followed by 
IFN-γ and IL-17 but was less eﬀective in suppressing IL-4. We observed a similar pattern after ex 
vivo stimulation of whole blood of GPA patients and healthy controls (chapter 4). Interestingly, 
it has been shown that TCR induced Ca2+ signaling is lower in T
H





and, naïve T cells66, 67. This suggests that Kv1.3 mediated T cell activation is diﬀerentially regulated 
between T cell subsets which might explain why ShK-186 mediated Kv1.3 channel blockade has 
a more pronounced eﬀect on the production of the pro-inﬂammatory cytokines IFN-γ and IL-17 
compared to IL-4. However, it has also been reported that ShK-186 signiﬁcantly reduced IL-4 and 
IL-5 production by allergen-stimulated peripheral T cells from subjects with asthma, suggesting 
selectivity towards T
H
2 cells in asthma patients68. In addition, recent data suggest that antigen-
speciﬁc T cell are programmed towards Kv1.3 dependency which is enforced by chronic antigen 
stimulation69. Thus, irrespective of the T cell phenotype, the susceptibility to Kv1.3 blockade 
is a property of repeatedly stimulated antigen-speciﬁc T cells. Therefore, T cells derived from 
autoimmune disease patients chronically exposed to the auto-antigens contain a pool of T
EM
 
cells amenable to Kv1.3 inhibition. Future studies in GPA should assess whether PR3 speciﬁc 




Modulation of B cell effector function in GPA by Kv1.3 blocker
Similar to the T cell lineage, Kv1.3 channels may serve as therapeutic targets for modulation 
of B cell function in autoimmune disorders. Four human B cell subsets can be distinguished 
based on the expression of IgD and CD2770. Mature naive B cells express IgD but not CD27. 
Acquisition of CD27 following somatic hypermutations results in a CD27+IgD+ memory B cells 
subsets71. Next, during Ig class switching replacement of the surface IgD with other Ig isotypes 
yields CD27+IgD- class switched memory B cells. These class switched memory B cells are the 
precursors of the (auto)antibody producing plasma cells and contribute importantly to antibody 
independent B cell eﬀector functions via secretion of pro-inﬂammatory cytokines72. Hence, class 
switched memory B cells have been shown to contribute to the aberrant immune response via 
(auto)antibody-dependent and (auto)antibody-independent functions in MS, T1D, and RA73, 74, 
75. Interestingly, Kv1.3 channels are highly expressed on the class switched memory B cells while 
naive and switched memory B cells express low levels of Kv1.3 channels76. 
In chapter 5 we investigated the eﬀect of Kv1.3 channel blockade using ShK-186 on B cell 
functions including proliferation, cytokine and (auto)antibody production. We observed that 
PBMCs from GPA patients treated with ShK-186 have a decreased production of both total and 
7
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PR3-ANCA speciﬁc IgGs. The reduction in IgG and ANCA was not due to decreased proliferation 
of total B cells. Furthermore, Kv1.3 channel blockade resulted in a signiﬁcant decrease in 
cytokine production of B cells. More speciﬁcally, a pronounced eﬀect was observed on the 
production of the pro-inﬂammatory cytokines TNF-α, IFN-γ and IL-2, whereas production of 
the anti-inﬂammatory cytokine IL-10 was less aﬀected. Consequently, the TNF-α/IL-10 ratio was 
signiﬁcantly decreased in the presence of ShK-186 indicating that Kv1.3 blockade skews the B cell 
response towards a more pronounced regulatory phenotype. However, since these eﬀects were 
observed on B cells during in vitro stimulation of total PBMCs, we cannot exclude an indirect 
eﬀect of T cells, especially because T cell help is required for the production of IgG. To unravel a 
direct eﬀect of ShK-186 on B cells, experiments with sorted B cell subsets should be performed.
Effector and regulatory B cells 
B cells are central to the pathogenesis of GPA as they are the precursors of the ANCA producing 
plasma cells. Besides ANCA production, B cells exhibit multiple other functions including antigen 
presentation and the production of various pro- and anti-inﬂammatory cytokines77, 78. Thus, B 
cells are involved in the pathogenic eﬀector processes in GPA but may also participate in the 
regulation of (auto)immune responses. Indeed, cytokine production by B cells inﬂuences the T
H
 





2 responses while the anti-inﬂammatory cytokines (e.g. IL-10) can suppress immune 
responses and skew T cell towards a regulatory phenotype47, 79-81. As such, the so-called regulatory 
B (B
REG
) cells have been described to inhibit the production of pro-inﬂammatory cytokines from 
monocytes and eﬀector T
H
 cells and to support the function of regulatory T cells82, 83. Therefore, 
considering the eﬀector and regulatory function of B cells, the question remains whether 
complete depletion of B cells following rituximab (RTX) treatment is the best treatment option. 
It might be desirable to speciﬁcally target the eﬀector B cells without impairing the regulatory 
B cell compartment.
Although B and T cells have their unique eﬀector function in physiological immune responses, 
these cells do not act separately. To mount an optimal immune response, a close interplay 
between B and T cells, either via direct cell contact or cytokine secretion, is necessary. In this 
context, B cells with immune regulatory properties, termed regulatory B (B
REG
) cells, have gained 
increasing interest in recent years. In particular, B
REG
 cells that can be phenotypically identiﬁed as 
IL-10 producing CD24hiCD38hi B cells were demonstrated to exert immune-regulating properties82. 
The mechanism of B
REG
-mediate suppression occurs primarily via the production of IL-10. As such, 
IL-10 producing B
REG
 cells have been shown to inhibit the activation of T
H
1 responses, inhibit the 
diﬀerentiation into T
H
17 cells, and to convert CD4+ T cells into regulatory T cells83, 84. In addition, 
besides the anti-inﬂammatory mediator IL-10, engagement of costimulatory molecules like 
CD80 and CD86 on B
REG
 cells also enhances the inhibition of T
H
1 responses83. Furthermore, an 
aberrant distribution and function of CD24hiCD38hi B
REG
 cells is associated with progression of 
several autoimmune disease including SLE and RA83, 84. These studies have demonstrated that 
these impaired B
REG
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and to convert CD4+ T cells into T
REG
 cells. Therefore, B
REG
 cells may be important in dampening 
the inﬂammatory responses in autoimmune diseases. 
In AAV it has been reported that the frequency of circulating B
REG
 cell is signiﬁcantly 
decreased, although their function in terms of IL-10 production and suppression of immune cell 
activity is not compromised85. In chapter 6 we investigate whether the decreased proportion of 
B
REG
 cells may explain the enhanced T
H
17 cell response in GPA patients. We showed a signiﬁcant 
inverse correlation between T
EM
17 cells and B
REG
 in GPA patients, which suggests that a decrease 
B
REG
 cell populations allows the T
H
17 cells to expand. Moreover, in co-culture experiments we 
demonstrated a signiﬁcant increase in the frequency of IL-17+ producing T
H
 cells in B
REG
 depleted 
cultures compared to the undepleted B
REG
 cultures. This observation is in line with other studies 
that indicate similar interactions between B
REGs
 cells and T
H
 cells83, 84. These studies reported that 
B
REG
 cells were able to decrease cytokine production of T
H
 cells and suppress their diﬀerentiation. 




17 cells may be derived from data of rituximab 
treated patients. It has been demonstrated that RTX reduces the T
H
17 response in RA patients, 




 cells, and TNF-α responses86. In addition, the inhibition of 
the T
H
17 response by RTX was lost in the absence of B cells, supporting the contention that B 
cells directly aﬀect T
H
17 responses. When B cells reconstitute following B cell depletion by RTX, 
CD24hiCD38hi B
REG
 form the initial (immature) B cell subset to repopulate the B cell compartment 
and may even become the dominant circulating B cell subset87, 88. Thus, enrichment of the 
CD24hiCD38hi B
REG
 subset upon B cell reconstitution after RTX treatment may aﬀect T
H
 cell 
distribution with a major eﬀect on T
H
17 cells86. However, the way in which B
REG
 cells inhibit T
H
17 
responses in inﬂammatory conditions remains to be elucidated. Yet, the suppressive functions 
of B
REG
 cells are most likely mediated via the engagement of a combination of several molecules 
including CD40 TLR and BCR signaling as well as CD80, CD86, and the production of immune 
regulatory cytokine such as IL-10, TGF-β and IL-3589. 
Of note, the CD24hiCD38hi B
REG
 cells can be identiﬁed within the naïve or transitional B 
cell compartment70, 83. These B cells lack the expression of CD27. Interestingly, it has been 
demonstrated that the CD27- B cells have lower numbers of Kv1.3 channels compared to the class 
switched memory B cells and therefore are likely to be less sensitive to Kv1.3 channels blockade76. 
Future studies are required to elucidate whether indeed B
REG
 cells escape the eﬀects of ShK-
186 due to lower numbers of Kv1.3 channels expressed and continue to exert their suppression 
function. 
B and T cell targeted therapies in GPA: Implications and future perspectives
The importance of targeting the eﬀector CD4+ T
EM
 cells and eﬀector memory B cells is 
emphasized by the fact that current treatments are directed against either the full spectrum 
of the immune system by using broad acting immune suppressive drugs, or T / B cell directed 
therapies that block the activation and/or migration of all T / B cell populations. In GPA, several 
T cell directed therapies are currently under investigation including drugs that either deplete T 
cells, block the pro-inﬂammatory eﬀect of TNF-α, or inhibit co-stimulatory signals needed for 
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T cell activation. For example, alemtuzumab is a humanized anti-CD52 monoclonal antibody 
(CAMPATH-1H) capable of selectively depleting peripheral circulating T lymphocytes, monocytes 
and macrophages. Alemtuzumab has been studied in a small uncontrolled trial of AAV patients 
in whom all immunosuppressant drugs had been discontinued (except for low dose (<10mg/
day) prednisolone) 90. The majority of patients achieved clinical remission, but a signiﬁcant 
proportion of these patients relapsed at a median time interval of 9 months after completion of 
the therapy. Also, adverse events such as severe infection and malignancies were reported in the 
alemtuzumab treated group90. 
Another approach to inﬂuence T cells responses in GPA is via interference with co-stimulatory 
molecules. The costimulatory blocker abatacept is a fusion protein of the protein cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4) and the immunoglobulin Fc region. Abatacept 
inhibits costimulatory signaling and consequently inhibits the activation of T cells. In a small, 
open-label prospective trial in GPA patients addition of abatacept to standard maintenance 
treatment with glucocorticoids was well tolerated and associated with a high frequency of 
disease remission91. An additional clinical trial with abatacept for the treatment of relapsing and 
non-severe GPA patients is currently running (ClinicalTrials.gov, NCT02108860). 
Besides targeting the T cells, trials have been conducted against individual cytokines that 
are considered to play a major role in the pathogenesis of AAV. For instance, the eﬃcacy of anti-
TNF-α treatment using etanercept (ETA) or inﬂiximab (IFX) has been investigated in AAV92, 93. In 
the Wegener’s Granulomatosis Etanercept Trail (WGET), ETA was evaluated as adjuvant treatment 
to standard therapy. This trial showed that ETA was not eﬀective for the maintenance of remission 
in patients with GPA92. In addition, there was a high rate of treatment-related complications in the 
group that had received ETA including a higher incidence of solid malignancies92, 94. Although 
AAV patients treated with IFX have been reported to enter clinical remission, an additional 
clinical beneﬁt of IFX over standard therapy was not reached93. As such the addition of IFX to 
standard therapy did not inﬂuence remission rates, adverse events, or relapse rates. Furthermore, 
a comparison between IFX with RTX for remission induction in patients with severe refractory 
GPA favors the use of RTX95. These data together with the results of the WGET study results have 
led to the abandonment of both ETA and IFX for the treatment of AAV. 
Treatment strategies aimed to aﬀect B cells in autoimmune diseases comprise anti-BAFF with 
or without simultaneous blockade of a proliferation-inducing ligand (APRIL) (i.e. belimumab, 
tabalumab and atacicept) but, so far, have failed to show clinical eﬃcacy in trials in SLE, MS, and 
RA patients96-100. Recently, a trial in AAV patients with anti-BAFF therapy has been completed 
but results have not been reported yet (ClinicalTrials.gov, NCT01663623). Although these agents 
are directed against mature B cells and short-lived plasma cells, the memory B cells are not 
aﬀected101. Especially class switched memory B cells appear to be resistant to BAFF depletion102. 
Anti-CD20 B cell depleting studies using rituximab show beneﬁcial outcomes for patients 
with GPA and RA103-105. However, disease ﬂares have been observed after reconstitution of B cells, 
accompanied by an increase in ANCA levels106. Also, a concern of long-term RXT treatment is 
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CD4+ cell counts have been linked to recurrent infections in RTX-treated patients107. Overall, the 
therapeutic agents currently under investigation, some more promising than others, do not 
adequately target either the eﬀector CD4+ T
EM
 or the eﬀector class switched memory B cells. 
In contrast to the therapeutic strategies described above, ShK-186 is unique in blocking a 
subset of the chronically activated T cell population, the CD4+ T
EM
 cells, and eﬀector memory B 
cells, the class switched memory B cells, both involved in the pathogenesis of GPA. Moreover, the 
use of ShK-186 in in vitro and in vivo models showed that other T and B cell populations (i.e. naïve T 
cells, T
CM
, naïve B cells, and unswitched memory B cells) remain largely unaﬀected52, 76. Treatment 
with ShK-186 inhibits the production of pro-inﬂammatory cytokines and therefore may have a 
more potent eﬀect than therapies directed against a single cytokine. It may also constitute a 
much more speciﬁc therapy by targeting the most potent pathogenic T and B cell subsets in GPA 
(chapter 4 and 5). Currently, ShK-186 has been given the FDA approved name dalazatide and 
has been studied in a phase 1a clinical trial in healthy volunteers (ClinicalTrials.gov, NCT02446340) 
and in a phase 1b clinical trial with psoriasis patients (ClinicalTrials.gov, NCT02435342). Both 
trials were designed to evaluate the safety, tolerability, and pharmacodynamics of dalazatide. 
These ﬁrst clinical trials with dalazatide indicate that the drug is safe and well tolerated. In 
the phase 1b trial, psoriasis patients treated twice weekly with dalazatide showed improved 
skin lesions associated with reduced plasma levels of multiple inﬂammatory markers and a 
reduced expression of T cell activation markers on the peripheral blood memory T cells of these 
patients108. This observation highlights that twice weekly administration of ShK-186 is suﬃcient 
to achieve blood levels required for suppressing CD4+ T
EM
 cells. Moreover, the study showed 
that the therapeutic potential of dalazatide, which is an unconjugated small molecular mass 
peptide, is viable. This avoids additional engineering costs to enhance the pharmacokinetic 
and pharmacodynamic properties keeping the overall expenses low in comparison to other 
currently developed biologicals. In addition, based on the durable pharmacological responses 
and therapeutic eﬀects of ShK-186, treatment could be paused in the event of an acute infection 
which would be an added beneﬁt compared to current treatments in GPA (i.e. cyclophosphamide, 
high dose corticosteroids and rituximab) of which the eﬀects take several months to subside. To 
date, dalazatide awaits further phase 2 trials for several systemic autoimmune diseases. 
Although the list of treatment possibilities for GPA and autoimmune diseases in general oﬀers 
interesting alternatives for these patients, the disease-causing cells such as the auto reactive T 
cells and especially the auto reactive B / plasma cells responsible for ANCA production remain 
largely unaﬀected. Interestingly, intriguing developments are taking place at present in the 
ﬁeld of immune-oncology with regard to the use of cell-based immunotherapies. Studies show 
that the anti-tumor function of T cells can be genetically enhanced via the addition of chimeric 
antigen receptors (CARs). CARs are immunoreceptors consisting of the antigen-recognition 
domain of an antibody linked to the cytoplasmic T-cell signaling domain and co-stimulatory 
domains. The CAR-T cells are designed to recognize extracellular tumor-associated antigens and 
eliminate the tumor cells. Currently, the most notable example of CAR-T cell therapy are the 
CAR-T cells that target CD19. These CAR-T cells have shown remarkable antitumor activity in 
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patients with refractory B-cell malignancies such as acute lymphoblastic leukemia (ALL) and non-
Hodgkin lymphoma (NHL) 109, 110. Theoretically, a similar strategy could also be applied to target 
and eliminate autoreactive B cells. In a ﬁrst proof of principle study, Ellebrecht et al. reengineered 
CAR T cells into chimeric autoantigen receptor (CAAR) T cells designed to speciﬁcally eliminate 
desmoglein 3 (Dsg3)-speciﬁc autoreactive B cells responsible for the blistering autoimmune 
disease pemphigus vulgaris in vivo111. Using a murine model, the authors demonstrated that Dsg3 
CAAR-T cells exhibited speciﬁc cytotoxicity against B cells bearing anti-Dsg3 B cell receptors in 
vitro and speciﬁcally eliminated Dsg3-speciﬁc B cells in vivo. Since for GPA the auto-antigens (i.e. 
PR3 or MPO) are known it is intriguing to consider such a CAAR T cell approach to eliminate PR3 
or MPO autoreactive B cells in AAV as well. 
Overall, future therapeutic strategies in AAV, whether they make use of small peptides, 
biologicals or live T cell-based therapies, should target either speciﬁc cellular players or other 
disease speciﬁc mechanisms aimed to improve speciﬁcity and reduce treatment related toxicity. 
Concluding remarks 
The data presented in this thesis contribute to our knowledge on the T and B cell eﬀector 




17 cells within 
the CD4+ T
EM





17 cells appears to be associated with severity of the disease. In addition, 
we showed that a diminished B
REG
 cell number may contribute to the increased T
H
17 response 
in GPA patients. 
Considering the high expression of Kv1.3 channels on the surface of CD4+ T
EM
 cells and 
switched memory B cells combined with their involvement in the pathogenesis of GPA, speciﬁc 
Kv1.3 blockade could be an attractive therapeutic option. Here, we showed that the Kv1.3 blocker 
ShK-186 (dalazatide) modulates pro-inﬂammatory eﬀector functions of blood derived CD4+ T 
cells and B cells from GPA patients in vitro. For CD4+ T cells, ShK-186 predominantly inhibited 
cytokine production of CD4+ T
EM
 cells, whereas for B cells we showed that ShK-186 skews these 
cells towards a more pronounced regulatory B cell response. However, given the limited data 
available to date, future studies should investigate whether and how ShK-186 treatment aﬀects 
the function of regulatory T and B cells directly. Also, the long-term immunomodulatory eﬀects 
of ShK-186 should be studied since long-term ShK-186 treatment could polarize eﬀector T and B 
towards an anti-inﬂammatory regulatory T and B cell proﬁle. In this context, in vivo studies using 
the experimental autoimmune vasculitis rat model for ANCA-associated vasculitis might be 
helpful to study long-term immunomodulatory eﬀects of ShK-186112. Such studies may provide 
valuable information on whether an enhanced regulatory immune proﬁle is safe. 
In conclusion, the results presented in this thesis support the contention that selective Kv1.3 
channel blockade using ShK-186 may be an attractive therapeutic option for T and B eﬀector 
subset-selective immunomodulation in GPA. Further in vitro and in vivo studies are necessary 
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